Literature DB >> 22273595

Extracorporeal machine liver perfusion: are we warming up?

Amelia J Hessheimer1, Constantino Fondevila, Juan C García-Valdecasas.   

Abstract

PURPOSE OF REVIEW: Recently, considerable focus has been placed on the use of hypothermic perfusion ex vivo in abdominal organ transplant. Herein, we discuss the appropriateness of using this modality to preserve livers, in particular those of suboptimal quality, and whether perfusing at warmer temperatures in this context may, in fact, be better. RECENT
FINDINGS: Hypothermic perfusion (0-4°C) appears to improve the hepatocellular energy charge and achieve adequate results in normal livers. However, its use for the preservation of suboptimal grafts may lead to significant endothelial and Kupffer cell injury that is incompatible with survival. Studies on the perfusion of suboptimal livers at higher temperatures, on the contrary, indicate that results improve as temperatures approach 37°C, provided that the oxygen supply during perfusion is adequate.
SUMMARY: Normothermic perfusion provides oxygen and other metabolic substrates under physiological conditions; in liver transplant, it appears to be the best option to improve the viability of suboptimal organs.

Entities:  

Mesh:

Year:  2012        PMID: 22273595     DOI: 10.1097/MOT.0b013e328351082a

Source DB:  PubMed          Journal:  Curr Opin Organ Transplant        ISSN: 1087-2418            Impact factor:   2.640


  8 in total

Review 1.  Perfusion machines for liver transplantation: technology and multifunctionality.

Authors:  Michele Rubbini
Journal:  Updates Surg       Date:  2013-09-20

2.  Criteria for viability assessment of discarded human donor livers during ex vivo normothermic machine perfusion.

Authors:  Michael E Sutton; Sanna op den Dries; Negin Karimian; Pepijn D Weeder; Marieke T de Boer; Janneke Wiersema-Buist; Annette S H Gouw; Henri G D Leuvenink; Ton Lisman; Robert J Porte
Journal:  PLoS One       Date:  2014-11-04       Impact factor: 3.240

3.  Technique of subnormothermic ex vivo liver perfusion for the storage, assessment, and repair of marginal liver grafts.

Authors:  Jan M Knaak; Vinzent N Spetzler; Nicolas Goldaracena; Kristine S Louis; Nazia Selzner; Markus Selzner
Journal:  J Vis Exp       Date:  2014-08-13       Impact factor: 1.355

4.  Normothermic Machine Perfusion of Deceased Donor Liver Grafts Is Associated With Improved Postreperfusion Hemodynamics.

Authors:  Roberta Angelico; M Thamara P R Perera; Reena Ravikumar; David Holroyd; Constantin Coussios; Hynek Mergental; John R Isaac; Asim Iqbal; Hentie Cilliers; Paolo Muiesan; Peter J Friend; Darius F Mirza
Journal:  Transplant Direct       Date:  2016-08-05

5.  Heme oxygenase-1-modified bone marrow mesenchymal stem cells combined with normothermic machine perfusion to protect donation after circulatory death liver grafts.

Authors:  Huan Cao; Liu Yang; Bin Hou; Dong Sun; Ling Lin; Hong-Li Song; Zhong-Yang Shen
Journal:  Stem Cell Res Ther       Date:  2020-06-05       Impact factor: 6.832

Review 6.  Ubiquitin-proteasome system and oxidative stress in liver transplantation.

Authors:  Norma Alva; Arnau Panisello-Roselló; Marta Flores; Joan Roselló-Catafau; Teresa Carbonell
Journal:  World J Gastroenterol       Date:  2018-08-21       Impact factor: 5.742

7.  Normothermic Ex Vivo Liver Platform Using Porcine Slaughterhouse Livers for Disease Modeling.

Authors:  Melanie Krüger; Alicia Ruppelt; Benjamin Kappler; Elke Van Soest; Roos Anne Samsom; Guy C M Grinwis; Niels Geijsen; J Bernd Helms; Marco Stijnen; Linda M Kock; Marco Rasponi; Hans S Kooistra; Bart Spee
Journal:  Bioengineering (Basel)       Date:  2022-09-14

8.  Hypothermic oxygenated machine perfusion prevents arteriolonecrosis of the peribiliary plexus in pig livers donated after circulatory death.

Authors:  Sanna Op den Dries; Michael E Sutton; Negin Karimian; Marieke T de Boer; Janneke Wiersema-Buist; Annette S H Gouw; Henri G D Leuvenink; Ton Lisman; Robert J Porte
Journal:  PLoS One       Date:  2014-02-14       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.